# SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues

> **NCT06832150** · — · ENROLLING_BY_INVITATION · sponsor: **The Wellcome Sanger Institute** · enrollment: 60 (estimated)

## Conditions studied

- Somatic Mutation
- Cancer

## Interventions

- **OTHER:** sample collection
- **OTHER:** Discussing study
- **OTHER:** Seeking consent

## Key facts

- **NCT ID:** NCT06832150
- **Lead sponsor:** The Wellcome Sanger Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-11-26
- **Primary completion:** 2028-05-14
- **Final completion:** 2029-05-13
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06832150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06832150, "SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06832150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*